In recent years, osimertinib has attracted a lot of attention among lung cancer experts. Results from the Phase 3 LAURA trial received a standing ovation at the 2024 American Society of Clinical Oncology Annual Meeting after the trial demonstrated a progression-free survival benefit of 33.5 months in patients with EGFR-mutated, unresectable stage 3 non-small cell […]